In this multicentre , randomised phase III trial with @ design , patients with FIGO stage IIb-IV EOC were randomised to six cycles PCw ( paclitaxel @mg/m ( @ ) , cisplatin @mg/m ( @ ) or carboplatin AUC @ ) or three cycles PC@w ( paclitaxel @mg/m ( @ ) , cisplatin @mg/m ( @ ) or carboplatin AUC @ ) , followed by either three or six cycles PC@w .